

Freedom of Information Request: Our Reference CTMUHB_112_22

You asked:

Q1. In the last 6 months, how many patients has your Health Board treated (for any condition) with the following treatments

- **Avatrombopag**
- **Eltrombopag**
- **Fostamatinib**
- **Romiplostim**

Please find below a table populated with the data that Medicines Management are able to provide in relation to Q1. The period the data relates to is the latest 6 months available October 2021 to March 2022.

Medicine	Number of Patients
Avatrombopag	0
Eltrombopag	10
Fostamatinib	0
Romiplostim	**

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. In the last 6 months, how many patients has your Health Board treated for Immune thrombocytopenia (ICD10 code D69.3)?

For the date range 01.04.21 – 30.09.21, 5 patients have been treated for Immune Thrombocytopenia (ICD10 code D69.3).

Q3. In the last 6 months, how many patients has your Health Board treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

- **Avatrombopag**
- **Mycophenolate mofetil**
- **Rituximab**
- **Surgery (splenectomy)**

The Health Board will not provide specific treatment details for Immune thrombocytopenia patients due to the small numbers involved (see response to Q2). It considers there is the potential for the individuals to be identified from the information provided when considered with other information that may also be in the public domain. Therefore, the Health Board has relied upon section 40(2) of the Act in respect of this request.

Q4. Does your Health Board participate in any clinical trials for the treatment of Immune thrombocytopenia? If so, can you please provide the name of each trial and the number of patients taking part.

We can confirm that the Health Board are not currently participating in any clinical trials for the treatment of Immune thrombocytopenia.